Description

Ethyl 8-Bromo-5-Methyl-6-Oxo-5,6-Dihydro-4H-Benzo[F]Imidazo[1,5-A][1,4]Diazepine-3-Carboxylate is a high-purity, advanced pharmaceutical intermediate with the CAS registry number 78756-37-3. This compound is valued for its role as a critical building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly within the benzodiazepine analog class. It is essential for research and development chemists and manufacturers in the pharmaceutical and biotechnology sectors seeking to develop new therapeutic agents.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of novel benzodiazepine-based active pharmaceutical ingredients (APIs) for central nervous system (CNS) research.
• Medicinal Chemistry Research: Used in lead optimization and structure-activity relationship (SAR) studies to develop new therapeutic compounds.
• Process Chemistry Development: Serves as a standard or starting material for scaling up synthetic routes in process R&D laboratories.
• Contract Manufacturing (CMO): Supplied to contract manufacturing organizations for the production of clinical trial materials or niche APIs.
• Academic Research: Utilized in university and institutional labs for studying heterocyclic chemistry and novel synthetic methodologies.
• Reference Standard: Can be supplied as a high-purity analytical standard for quality control and method development in analytical laboratories.

Basic Information

Product Name	Ethyl 8-Bromo-5-Methyl-6-Oxo-5,6-Dihydro-4H-Benzo[F]Imidazo[1,5-A][1,4]Diazepine-3-Carboxylate
CAS No.	78756-37-3
Molecular Formula	C₁₆H₁₄BrN₃O₃
Molecular Weight	376.21 g/mol
Synonyms	8-Bromo-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylic acid ethyl ester; Ethyl 8-bromo-5-methyl-6-oxo-4,5-dihydro-6H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; 78756-37-3; Benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylic acid, 8-bromo-5,6-dihydro-5-methyl-6-oxo-, ethyl ester
EINECS	Contact for details

Quality Control

Our Ethyl 8-Bromo-5-Methyl-6-Oxo-5,6-Dihydro-4H-Benzo[F]Imidazo[1,5-A][1,4]Diazepine-3-Carboxylate is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, to ensure it meets exacting specifications for pharmaceutical R&D. A comprehensive Certificate of Analysis (COA) detailing purity, related substances, and residual solvents is provided with every shipment to guarantee traceability and compliance.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.